Compare AMLX & GAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMLX | GAB |
|---|---|---|
| Founded | 2014 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2021 | N/A |
| Metric | AMLX | GAB |
|---|---|---|
| Price | $14.55 | $5.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $21.56 | N/A |
| AVG Volume (30 Days) | 948.4K | ★ 1.1M |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.91% |
| EPS Growth | ★ 65.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $380,786,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1612.94 | N/A |
| 52 Week Low | $4.64 | $5.28 |
| 52 Week High | $18.61 | $6.37 |
| Indicator | AMLX | GAB |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 50.21 |
| Support Level | $13.02 | $5.48 |
| Resistance Level | $15.37 | $6.22 |
| Average True Range (ATR) | 0.86 | 0.09 |
| MACD | -0.32 | 0.01 |
| Stochastic Oscillator | 0.00 | 61.82 |
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.